biostudies-literatureUnknown9Choi JM<h4>Background</h4>Non-alcoholic fatty liver disease (NAFLD) and <i>Helicobacter pylori</i> (<i>Hp</i>) infection have a close association with an increased risk of cardiovascular disease. Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by metabolic dysfunction in NAFLD. We investigated the synergistic effects of NAFLD/MAFLD and <i>Hp</i> infection on the risk of arterial stiffness in an asymptomatic population.<h4>Methods</h4>We included individuals who underwent abdominal ultrasonography, anti-<i>Hp</i> IgG antibody evaluations and cardio-ankle vascular index (CAVI) during health screening tests between January 2013 and December 2017. Arterial stiffness was defined using CAVI. A logistic regression model was used to analyze the independent and synergistic effects of NAFLD/MAFLD and <i>Hp</i> infection on the risk of arterial stiffness.<h4>Results</h4>Among 3,195 subjects (mean age 54.7 years, 68.5% male), the prevalence of increased arterial stiffness was 36.4%. In the multivariate analysis, subjects with NAFLD but without <i>Hp</i> infection and those with both NAFLD and <i>Hp</i> infection had a significantly higher risk of increased arterial stiffness [odds ratio (OR) 1.61, 95% confidence interval (CI) 1.15-2.26, and OR 2.23, 95% CI 1.63-3.06, respectively], than subjects without <i>Hp</i> infection and NAFLD. Regarding MAFLD, <i>Hp</i> infection additively increased the risk of arterial stiffness in subjects with MAFLD (OR 2.13, 95% CI 1.64-2.78).<h4>Conclusions</h4>An interactive effect of <i>Hp</i> infection on the risk of arterial stiffness in individuals with NAFLD/MAFLD was observed. <i>Hp</i> infection additively increases the risk of arterial stiffness in subjects with NAFLD or MAFLD.Frontiers in medicine844954https://www.ebi.ac.uk/biostudies/studies/S-EPMC8914072biostudies-literatureNon-alcoholic/Metabolic-Associated Fatty Liver Disease and <i>Helicobacter pylori</i> Additively Increase the Risk of Arterial Stiffness.PMC8914072Choi JMPark HEChung SJLee JHan YMLee HYim JYChung GELim SHfalseNon-alcoholic/Metabolic-Associated Fatty Liver Disease and <i>Helicobacter pylori</i> Additively Increase the Risk of Arterial Stiffness.<h4>Background</h4>Non-alcoholic fatty liver disease (NAFLD) and <i>Helicobacter pylori</i> (<i>Hp</i>) infection have a close association with an increased risk of cardiovascular disease. Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by metabolic dysfunction in NAFLD. We investigated the synergistic effects of NAFLD/MAFLD and <i>Hp</i> infection on the risk of arterial stiffness in an asymptomatic population.<h4>Methods</h4>We included individuals who underwent abdominal ultrasonography, anti-<i>Hp</i> IgG antibody evaluations and cardio-ankle vascular index (CAVI) during health screening tests between January 2013 and December 2017. Arterial stiffness was defined using CAVI. A logistic regression model was used to analyze the independent and synergistic effects of NAFLD/MAFLD and <i>Hp</i> infection on the risk of arterial stiffness.<h4>Results</h4>Among 3,195 subjects (mean age 54.7 years, 68.5% male), the prevalence of increased arterial stiffness was 36.4%. In the multivariate analysis, subjects with NAFLD but without <i>Hp</i> infection and those with both NAFLD and <i>Hp</i> infection had a significantly higher risk of increased arterial stiffness [odds ratio (OR) 1.61, 95% confidence interval (CI) 1.15-2.26, and OR 2.23, 95% CI 1.63-3.06, respectively], than subjects without <i>Hp</i> infection and NAFLD. Regarding MAFLD, <i>Hp</i> infection additively increased the risk of arterial stiffness in subjects with MAFLD (OR 2.13, 95% CI 1.64-2.78).<h4>Conclusions</h4>An interactive effect of <i>Hp</i> infection on the risk of arterial stiffness in individuals with NAFLD/MAFLD was observed. <i>Hp</i> infection additively increases the risk of arterial stiffness in subjects with NAFLD or MAFLD.2022-01-01T00:00:00Z20222025-04-27T01:03:40.5Z2025-04-06T18:05:46.344ZS-EPMC89140723528089510.3389/fmed.2022.844954